DENVER, Sept. 10, 2019 /PRNewswire/ -- CereHealth Corporation through its subsidiary CereScan ®, a national network of functional brain imaging and analytics centers, announced today that it has ...
Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...
Therapeutic strategies in Parkinson's disease (PD) provide control of motor (nigral) and nonmotor (extranigral) symptoms. Nigral dopamine-related signs and symptoms are addressed by supplementation or ...
Physicians now have an objective test to evaluate patients for Parkinsonian syndromes, such as Parkinson's disease. DaTscan™ is the only FDA-approved imaging agent for assessment of movement disorders ...
The Parkinson’s Progression Markers Initiative (PPMI) was launched in July with hopes of identifying a biomarker, or set of markers, that tracks the natural course of Parkinson disease in 400 newly ...
January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...
Study: Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson’s disease. Image Credit: mozakim / Shutterstock.com Parkinson’s disease (PD) is a neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback